This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2015 Sep;33(9):902-4.

doi: 10.1038/nbt.3332.

The payers' perspective on gene therapies

Nicolas Touchot¹, Mathias Flume²

Affiliations

Affiliations

¹ groupH, Strategy Consulting, London, UK.
² Kassenärztliche Vereinigung Westfalen Lippe, Prescription Management, Dortmund, Germany.

PMID: 26348952
DOI: 10.1038/nbt.3332

Comment

The payers' perspective on gene therapies

Nicolas Touchot et al. Nat Biotechnol. 2015 Sep.

. 2015 Sep;33(9):902-4.

doi: 10.1038/nbt.3332.

Authors

Nicolas Touchot¹, Mathias Flume²

Affiliations

¹ groupH, Strategy Consulting, London, UK.
² Kassenärztliche Vereinigung Westfalen Lippe, Prescription Management, Dortmund, Germany.

PMID: 26348952
DOI: 10.1038/nbt.3332

No abstract available

PubMed Disclaimer

Comment on

The special case of gene therapy pricing.
Brennan TA, Wilson JM. Brennan TA, et al. Nat Biotechnol. 2014 Sep;32(9):874-6. doi: 10.1038/nbt.3003. Nat Biotechnol. 2014. PMID: 25203033

References

1. Nat Biotechnol. 2014 Sep;32(9):874-6 - PubMed
1. J Viral Hepat. 2015 Apr;22(4):376-83 - PubMed
1. Mol Ther. 2015 Feb;23(2):217-8 - PubMed

Publication types

Actions

MeSH terms

Actions
Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
Medical
- MedlinePlus Health Information